In a paper published on the Lancet pre-print server, researchers report that both mixed schedules (Pfizer / BioNTech followed by Oxford / AstraZeneca, and Oxford / AstraZeneca followed by Pfizer / BioNTech) induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered 4 weeks apart.